Mechanism and Clinical Efficacy of Peripheral Blood Alive Cell Treatment on Androgenic Alopecia

The study investigated the efficacy and safety of peripheral blood alive cell treatment (ACT) for androgenic alopecia (AGA) in 60 male volunteers, divided into ACT and ACT + finasteride (FNS) groups. Both groups showed significant increases in hair counts after 6 months, with the ACT + FNS group showing improvements at both 3 and 6 months. The efficacy rates were 75.0% for ACT and 81.3% for ACT + FNS, with no significant difference between the groups. ACT was found to promote hair follicle cell proliferation, migration, and blood circulation, reduce cell apoptosis, and activate Wnt/β-catenin signaling. The treatments were effective and safe, showing promising clinical potential for AGA.